- Poseida Therapeutics Inc PSTX has entered into a strategic collaboration and license agreement with Roche Holdings AG RHHBY, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies.
- The collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas, and other hematologic indications.
- Under the agreement, Roche will receive from Poseida either exclusive rights or options to develop and commercialize several allogeneic CAR-T programs in Poseida's portfolio.
- Poseida's P-BCMA-ALLO1, an allogeneic CAR-T for multiple myeloma, is in Phase 1 study, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T for B-cell malignancies with an IND, expected in 2023.
- For a subset of the Poseida portfolio programs licensed or optioned to Roche, Poseida will conduct the Phase 1 studies and manufacture clinical materials before transitioning the programs to Roche for further development and commercialization.
- Roche will be solely responsible for the late-stage clinical development and global commercialization.
- Poseida will receive $110 million upfront and could receive up to $110 million in near-term milestones.
- In addition, Poseida is eligible to receive up to $6 billion in milestone payments.
- Price Action: PSTX shares are up 60.10% at $3.89 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in